FWBI 81X Upside Potential according to this Analyst!On 5/26/2022 Roth Capital brokerage Lowered the Price Target for First Wave BioPharma, Inc. (FWBI) from $600.00 to $270.00 giving a Buy Rating for the stock!
The stock is now at a historic low: $3.31.
In January 2021 it was $788.
Just to reach the Analyst Price Target, it need to grow 81.5X from this level.
The Market cap is extremely low: 4.58 Mil. 81X would be $371 Mil.
And wouldn`t be too much, if we look at their pipeline: 2 candidates reaching Phase 3 clinical trials, 3 candidates in Phase 2 and one in Phase one, in the following fields: Digestive/Nutritional Diseases, Inflammatory Diseases and Oncology.
It can explode anytime.
Even though the institutional ownership it`s not high, some of the shareholders that recently reported increasing stakes in the company are: Goldman Sachs, Blackrock and Jane Street Group.
This one is a premium call in my opinion.
Looking forward to read your opinion about it.
Firstwavebiopharma
FWBI all time lowFirst Wave BioPharma is a clinical-stage biopharmaceutical company that specializes in the development of targeted, non-systemic therapies for gastrointestinal diseases.
52 Week Range 1.27 - 26.30
Now the price is close to all time low and looks like a buy opportunity!
FWBI Opportunities in Multi-Billion-Dollar Commercial MarketsJames Sapirstein
Chairman, President and CEO of First Wave BioPharma, Inc.:
"We now have development- and clinical-stage programs that span six GI indications with significant market size opportunities, including: COVID-19-related GI infections (estimated at $10 billion, for COVID-19 related anti-virals); ulcerative colitis, ulcerative proctitis and ulcerative proctosigmoiditis (estimated at $5 billion); Crohn’s disease (estimated at $7.4 billion); immune checkpoint inhibitor-associated colitis (estimated at $22 billion for immune checkpoint inhibitors); and exocrine pancreatic insufficiency (EPI), a dangerous digestive disorder that afflicts most patients with cystic fibrosis and chronic pancreatitis (estimated at $1.6 billion)."
Short term price target: 3.31, medium term: 6.44, end of 2022: 9.5.
